The present invention refers to desacyl ghrelin and its use in the treatment of the eating disorder hyperphagia. In particular, the present invention refers to a use of a desacyl ghrelin or an active peptide fragment thereof for the preparation of a pharmaceutical composition for the treatment of hyperphagia in a subject. Preferably, hyperphagia is associated with body weight gain and/or obesity, and most preferably, the subject has a body mass index BMI of 30.
展开▼
